ONLINE PERSPECTIVE

PERSPECTIVES ON CLASSIC ARTICLES

Metastasis Suppressor Genes

Patricia S. Steeg

Affiliation of author: Women’s Cancers Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Correspondence to: Patricia S. Steeg, PhD, Women’s Cancers Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bldg. 10, Rm. 2A33, Bethesda, MD 20892 (e-mail: steegp{at}mail.nih.gov).

Historical Perspective

The metastasis suppressor gene field was launched in 1988 with the publication of an article in JNCI identifying nm23 (1). Despite the devastating consequences of tumor metastasis, little of its molecular regulation was known in 1988. Most studies at that time focused on the acquisition of traits, principally those involved in invasion. The instability of metastatic cell lines in terms of their behavior, gene expression patterns, and karyotypic abnormalities was thought to preclude the existence of consistent underlying molecular events. Genes up- or down-regulated in metastasis were identified almost exclusively in rodent model systems. We took a different approach and compared seven cell lines derived from a single murine K-1735 melanoma using differential colony hybridization (1). All of the cell lines formed primary tumors on intravenous injection into syngeneic and nude mice, but they varied widely in metastatic potential. Differential colony hybridization identified one cDNA, nm23, whose expression was quantitatively reduced in five highly metastatic cell lines as compared with two related, less metastatic cell lines. A similar pattern was observed in an independent model system, NMU-induced rat mammary carcinomas.

The data suggested that consistent changes in gene expression occurr in metastasis, and that the expression of specific genes is reduced in tumors with high metastatic potential. The latter observation, occurring on the heels of the discovery of tumor suppressors (2), prompted the hypothesis that metastasis may also be controlled by suppressor genes. Both concepts, novel at the time, were hotly debated. The nm23 manuscript was rejected three times; one review, which I still have, questioned the entire experimental approach:

"This reviewer cannot understand the rationale of the entire experimental plan described here....As we know, when a cancer cell undergoes transformation (or acquires metastatic ability), 152 separate genes get turned on and 378 get turned off.... By studying correlates of phenotypic change, one has little if any chance of understandings its causes."

Time has proven this assertion unfounded. nm23 cDNAs have now been transfected into 10 different tumor cell lines. Injection of control and nm23- transfectants into mice has shown a statistically significant reduction in tumor metastatic potential by nm23 re-expression, with no effect on primary tumor size (311). This effect stands as the current operational definition of a metastasis suppressor.

Recent Scientific Contributions: Metastasis Suppressor Genes

The metastasis suppressor field is exploding. The advent of microarray profiling of gene expression, using both rodent model systems and human tumors, has produced a wealth of candidate genes. Chromosome transfections have also identified functional genomic regions. Confirmed metastasis suppressors include Nm23, Differentiation related gene (Drg-1) (12), Src-suppressed C Kinase substrate (SSeCKs) (13), Vitamin D3 up-regulated protein 1 (VDUP)(14), the CRSP3 transcriptional coactivator (14), Mitogen activated protein kinase kinase 4 (15), Raf kinase inhibitor Rkip (16), RhoGDI2 (17), Brms1 (18), Kiss-1 (19), Claudin-4 (20), and Kai1 (21). Most of these genes consistently have no effect on proliferation in vitro or primary tumor size in vivo.

Most of the metastasis suppressor genes would not have been identified a priori as being involved in the metastatic process. In particular, they do not appear to be involved in the well-studied processes of invasion or angiogenesis. As is also the case for many tumor suppressors, an extensive but incomplete hunt for the biochemical activity or pathway responsible for the suppression of metastasis is underway. Three conclusions have emerged from these studies:

1) Many metastasis suppressors act at the final stage of tumor cell colonization at the metastatic site. For both the Mkk4 and Kiss1 suppressors, transfectants reach the lungs at frequencies comparable to control transfectants but fail to either grow or survive (22,23). This observation provides strong evidence that re-expression of metastasis suppressor expression by micrometastatic tumor cells may have therapeutic effects on cancer progression. Metastasis suppressors are usually transcriptionally silenced, rather than mutated, in aggressive tumors. Thus, if well-tolerated agents could be identified that elevate metastasis suppressor expression and therefore function in micrometastatic tumor cells, this strategy might constitute a new therapeutic endeavor.

2) New activities continue to be linked to the metastatic process. Brms regulates gap junctional signaling between cells (24). Mkk4 may control the apoptotic response to stresses that occur in metastatic sites (25). Kiss-1 is thought to encode a precursor to a migration inhibitory cytokine, which binds to a G protein–coupled receptor (2628). SSeCKS is a scaffold protein for the protein kinase A (PKA) and PKC pathways (13).

3) Metastasis suppressors affect multiple points of well-known signal transduction pathways. The Map kinase pathway is influenced by Mkk4, Rkip, and Nm23 interaction with Ksr (29), a scaffold for the Erk pathway. Brms1 interacts with histone deacetylase complexes and is postulated to influence transcription (30), and CRSP3 is a transcriptional coactivator. Invasion-related signaling pathways are influenced by RhoGDI2. These data highlight the important intersection of metastasis suppressor research and classical drug discovery, validation, and preclinical testing: Most drugs are now tested in vivo on short-term xenografts of primary tumors, the majority of which do not have metastatic activity. However, many drugs impact the signaling pathways listed. It therefore stands to reason that in patients with metastatic disease the readout of these pathways may be different than in patients with localized disease caused by loss of metastasis suppressor expression. A drug with efficacy on a primary tumor may not show similar effects on a metastatic lesion, in which signaling pathways are quantitatively altered. Drugs must therefore be tested using metastatically competent preclinical models (31).

Recent Scientific Contributions: Nm23

Despite 15 years of work, more remains unknown about Nm23 than is known. However, research on this gene holds promise for both basic research and translational advances. Nm23 is known to be a family of eight proteins occurring in all cellular compartments (32). We know that this gene possesses metastasis suppressive activity in a variety of tumor cell types. In vitro correlates of suppression include reduced invasion, motility and soft agar colonization, and induction of differentiation.

Differentiation remains one of the key correlates of altered Nm23 expression in multiple model systems. Both in vitro and in vivo studies support a role for this gene in breast differentiation. Control- and nm23-H1 transfectants of the human MDA-MB-435 breast carcinoma cell line were cultured three-dimensionally in Matrigel in the laboratory of Dr. Mina Bissell. The nm23-H1 transfectants formed ascinar structures, secreted the basement membrane proteins laminin and type IV collagen to the basal side of the ascinus, and produced sialomucin (33). Recently, a team from France reported a knockout mouse for nm23-M1 (34). Nm23-M1-/- mice exhibited growth retardation and pronounced mammary defects. In virgin mice, ductal elongation and branching was poor and the mammary gland failed to fill the fat pad. These morphological differences were overcome in pregnancy, but a functional defect persisted in feeding pups. In cells of neural origin, including PC12 cells, C6 gliomas, and neuroblastomas, increased Nm23 expression has been associated with differentiation (3539). It is likely that the fundamental cellular role of Nm23 is in differentiation and that this same role contributes to a lower metastatic threshold in cells that express this gene.

The Nm23 pattern of expression in tumor cohorts has been somewhat clear in breast cancer but has been subject to an unending debate in other cancer types. Nm23 is not an independent prognostic or predictive factor in any cancer cell type. The breast cancer data support the conclusion that altered Nm23 expression levels may be of functional significance in human, as opposed to mouse or cell line, cancer. Of the many possible reasons for variability in immunohistochemical studies, two stand out. The specificity of various anti-Nm23 antibodies for the eight family members varies, as do their nonspecific binding patterns. Second, quantitation systems for proteins whose reduced expression signals poor outcome are conceptually difficult. What should constitute the poor-prognosis subset? A computer-generated cutpoint? Any low-expressing cells? Mostly low-expressing cells? Is the percentage of cells staining or rather the intensity of staining important? Is the comparison of tumor to surrounding normal cells important? The contribution of different grading systems to the disparity of conclusions is likely important. We rationalized that it takes only a few metastatic cells to kill a patient and classified tumors with a nest of low–Nm23 expressing cells as a putative poor-prognosis subset. This grading system generated a statistically significant correlation in our laboratory (40) as well as in others’ (4143). Cutpoints where mixed populations of Nm23+ and Nm23- cells fell into the poor-prognosis category also generated statistically significant correlations (44,45). Nm23 expression patterns in cohort studies remain more than an academic question, however. If we identify compounds to elevate Nm23 expression in micrometastatic tumor cells, patients will be enrolled in a clinical trial based on low Nm23 expression in their primary tumor. It’s time to get it "right."

I remain intrigued by studies in which Nm23 expression is consistently increased concomitantly with aggressiveness, as in neuroblastoma (46,47). The mechanism behind these stimulatory effects is incompletely known and may involve mutation (48), alternate forms of the protein (49), or involvement in distinct signaling pathways.

Determining the biochemical mechanism(s) by which Nm23 suppresses metastasis is of vital importance. Papers describing a new binding partner or activity for this protein appear almost weekly, and five biannual meetings have been held on this topic. At least four classes of Nm23 biochemical activities have been described that may mediate its biological effects, including protein–protein interactions (39,5059), regulation of GTP-binding protein function (6065), DNA-associated activities (6669), and histidine-dependent protein phosphotransferase activity (7072). Site-directed mutagenesis of nm23-H1, followed by transfection of the wild-type or mutated cDNAs into a human breast carcinoma cell line and readout of in vitro motility, have linked the histidine protein kinase activity of Nm23-H1 with motility suppression (7274), and we continue to search for physiologic substrates of this unusual activity. One substrate is the Kinase suppressor of ras (Ksr), a scaffold protein for the Erk Map kinase pathway (29). We are working on the hypothesis that Nm23-H1 binding and phosphorylation of Ksr may inactivate this scaffold protein, reducing Erk activation and metastatic colonization.

The next frontier in metastasis suppressor research lies in its incorporation into the therapy of cancer patients. Recent papers have documented that standard chemotherapeutic agents may work in part through modulation of metastasis suppressor expression and function (75). For Nm23, several compounds have been identified that can elevate its expression in metastatically competent cell lines in vitro (76,77). The field now awaits evidence of in vivo elevation of metastasis suppressor expression and concomitant reduction in metastatic burden in model systems, as well as improvements in the specificity of the agents. Such agents could contribute to the search for molecularly defined therapies that can render cancer a chronic, treatable disease.

REFERENCES

1 Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988;80:200–4.[Abstract]

2 Friend S, Bernards R, Rogelj S, Weinberg R, Rapaport J, Albert D, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986;323:643–6.[ISI][Medline]

3 Leone A, Flatow U, King CR, Sandeen MA, Margulies IM, Liotta LA, et al. Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell 1991;65:25–35.[ISI][Medline]

4 Leone A, Flatow U, VanHoutte K, Steeg PS. Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, colonization, and enzymatic activity. Oncogene 1993;8:2325–33.[ISI][Medline]

5 Baba H, Urano T, Okada K, Furukawa K, Nakayama E, Tanaka H, et al. Two isotypes of murine nm23/Nucleoside diphosphate kinase, nm23-M1 and nm23-M2, are involved in metastatic suppression of a murine melanoma line. Cancer Res 1995;55:1977–81.[Abstract]

6 Parhar RS, Shi Y, Zou M, Farid NR, Ernst P, Al-Sedairy S. Effects of cytokine mediated modulation of Nm23 expression on the invasion and metastatic behavior of B16F10 melanoma cells. Int J Cancer 1995;60:204–10.[ISI][Medline]

7 Fukuda M, Ishii A, Yasutomo Y, Shimada N, Ishikawa N, Hanai N, et al. Metastatic potential of rat mammary adenocarcinoma cells associated with decreased expression of nucleoside diphosphate kinase/nm23: reduction by transfection of NDP Kinase a isoform, an nm23-H2 gene homolog. Int J Cancer 1996;65:531–7.[CrossRef][ISI][Medline]

8 Bhujwalla Z, Aboagye E, Gilles R, Chack V, Mendola C, Backer J. Nm23-transfected MDA-MB-435 human breast carcinoma cells form tumors with altered phospholipid metabolism and pH: a 31P nuclear magnetic resonance study in vivo and in vitro. Magn Reson Med 1999;41:897–903.[CrossRef][ISI][Medline]

9 Russell R, Pedersen A, Kantor J, Geisinger K, Long R, Zbieranski N, et al. Relationship of nm23 to proteolytic factors, proliferation and motility in breast cancer tissues and cell lines. Br J Cancer 1998;78:710–7.[ISI][Medline]

10 Tagashira H, Hamazaki K, Tanaka N, Gao C, Namba M. Reduced metastatic potential and c-myc overexpression of colon adenocarcinoma cells (colon 26 line) transfected with nm23-R2 rat nucleoside diphosphate kinase a isoform. Int J Mol Med 1998;2:65–8.[ISI][Medline]

11 Miyazaki H, Fukuda M, Ishijima Y, Negishi A, Hirayama R, Ishikawa N, et al. Overexpression of nm23-H2/NDP kinase B in a human oral squamous cell carcinoma cell line results in reduced metastasis, differentiated phenotype in the metastatic site, and growth factor-independent proliferative activity in culture. Clin Cancer Res 1999;5:4301–7.[Abstract/Free Full Text]

12 Bandyopadhyay S, Pai S, Gross S, Hirota S, Hosobe S, Miura K, et al. The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res 2003;63:1731–6.[Abstract/Free Full Text]

13 Xia W, Unger P, Miller L, Nelson J, Gelman I. The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res 2001;61:5644–51.[Abstract/Free Full Text]

14 Goldberg S, Miele M, Hatta N, Takata M, Paquette-Straub C, Freedman L, et al. Melanoma metastasis suppression by chromosome 6: evidence for a pathway regulated by CRSR3 and TXNIP. Cancer Res 2003;63:432–40.[Abstract/Free Full Text]

15 Yoshida B, Dubauskas Z, Chekmareva M, Christiano T, Stadler W, Rinker-Schaeffer C. Mitogen-activated protein kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res 1999;59:5483–7.[Abstract/Free Full Text]

16 Fu Z, Smith P, Zhang L, Rubin M, Dunn R, Yao Z, et al. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 2003;95:878–89.[Abstract/Free Full Text]

17 Gildea J, Seraj M, Oxford G, Harding M, Hampton G, Moskaluk C, et al. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 2002;62:6418–23.[Abstract/Free Full Text]

18 Seraj M, Samant R, Verderame M, Welch D. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res 2000;60:2764–9.[Abstract/Free Full Text]

19 Lee J, Miele M, Hicks D, Phillips K, Trent J, Weissman B, et al. Kiss-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst 1996;88:1731–7.[Abstract/Free Full Text]

20 Michl P, Barth C, Buchholz M, Lerch M, Rolke M, Holzmann K-H, et al. Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res 2003;63:6265–71.[Abstract/Free Full Text]

21 Dong J, Lamb P, Rinker-Schaeffer C, Vukanovic J, Ichikawa T, Issacs J, et al. Kai1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995;268:884–6.[ISI][Medline]

22 Chekmareva M, Kadkhodaian M, Hollowell C, Kim H, Yoshida B, Luu H, et al. Chromosome 17-mediated dormancy of AT6.1 prostate cancer micrmetastases. Cancer Res 1998;58:4963–9.[Abstract]

23 Goldberg S, Harms J, Quon K, Welch D. Metastasis suppressed C8161 melanoma cells arrest in lung but fail to proliferate. Clin Exp Metast 1999;17:601–7.[CrossRef][ISI][Medline]

24 Saunders M, Seraj M, Li Z, Zhou Z, Winter C, Welch D, et al. Breast cancer metastastic potential correlates with a breakdown in homospecific and heterospecific gap junctionalintercellular communication. Cancer Res 2001;61:1765–7.[Abstract/Free Full Text]

25 Robinson V, Hickson J, Griend DV, Dubauskas Z, Rinker-Schaeffer C. MKK4 and metastasis suppression: A marriage of signal transduction and metastasis research. Clin Exp Metast. In press. 2002.

26 Kotani M, Detheux M, Vandenbogaerde A, Communi D, Vanderwinden J, LePoul E, et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GRP54. J Biol Chem 2001;276:34631–6.[Abstract/Free Full Text]

27 Muir A, Chamerbalin L, Elshourbagy N, Machalovich D, Moore D, Calamari A, et al. AXOR12, a novel human G protein-coupled receptor, activated by the peptide Kiss-1. J Biol Chem 2001;276:28969–75.[Abstract/Free Full Text]

28 Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K, et al. Metastasis suppressor Kiss-1 encodes a peptide ligand of a G-protein-coupled receptor. Nature 2001;411:613–7.[CrossRef][ISI][Medline]

29 Hartsough M, Morrison D, Salerno M, Palmieri D, Ouatas T, Mair M, et al. Nm23-H1 metastasis suppressor phosphorylation of kinase suppressor of ras (KSR), via a histidine protein kinase pathway. J Biol Chem 2002;277:32389–99.[Abstract/Free Full Text]

30 Meehan W, Samant R, Hopper J, Carrozza M, Shevde L, Workman J, et al. The BRMS1 metastasis suppressor forms complexes with RBP1 and the mSin3 histone deacetylase complex and represses transcription. J Biol Chem. In press. 2003.

31 Steeg P. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 2003;3:55–63.[CrossRef][ISI][Medline]

32 Lacombe M-L, Milon L, Munier A, Mehus J, Lambeth D. The human Nm23/nucleoside diphosphate kinases. J Bioenerg Biomembr 2000;32:247–58.[CrossRef][ISI][Medline]

33 Howlett AR, Petersen OW, Steeg PS, Bissell MJ. A novel function for Nm23: overexpression in human breast carcinoma cells leads to the formation of basement membrane and growth arrest. J Natl Cancer Inst 1994;86:1838–44.[Abstract]

34 Arnaud-Dabernat S, Bourbon P, Dierich A, LeMeur M, Daniel J. Knockout mice as model systems for studying nm23/NDP kinase gene functions. Application to the nm23-M1 gene. J Bioenerg Biomembr 2003;35:19–30.[CrossRef][ISI][Medline]

35 Ishijima Y, Shimada N, Fukada M, Miyazaki H, Orlov N, Orlova T, et al. Overexpression of nucleoside diphosphate kinases induced neurite outgrowth and their substitution to inactive forms leads to suppression of nerve growth factor- and dibutryl cAMP-induced effects in PC12D cells. FEBS Lett 1999;445:155–9.[CrossRef][ISI][Medline]

36 Lombardi D, Lacombe M, Paggi M. nm23: unraveling its biological function in cell differentiation. J Cell Physiol 2000;182:144–9.[CrossRef][ISI][Medline]

37 Negroni A, Venturelli D, Tanno B, Amendola R, Ransac S, Cesi V, et al. Neuroblastoma specific effects of DR-nm23 and its mutant forms on differentiation and apoptosis. Cell Death Differ 2000;7:843–50.[CrossRef][ISI][Medline]

38 Backer M, Kamel N, Sandoval C, Jayabose S, Mendola C, Backer J. Overexpression of NM23-1 enhances responsiveness of IMR-32 human neuroblastoma cells to differentiation stimuli. Anticancer Res 2000;20:1743–9.[ISI][Medline]

39 Roymans D, Willems R, Vissenberg K, DeJonghe C, Groben B, Claes P, et al. Nucleoside diphosphate kinase b (Nm23-R1/NDPKb) is associated with intermediate filaments and becomes upregulated upon cAMP-induced differentiation of rat C6 glioma. Exp Cell Res 2000;261:127–38.[CrossRef][ISI][Medline]

40 Barnes R, Masood S, Barker E, Rosengard AM, Coggin DL, Crowell T, et al. Low Nm23 protein expression in infiltrating ductal breast carcinomas correlates with reduced patient survival. Am J Pathol 1991;139:245–50.[Abstract]

41 Heimann R, Ferguson D, Hellman S. The relationship between nm23, angiogenesis, and the metastatic proclivity of node-negative breast cancer. Cancer Res 1998;58:2766–71.[Abstract]

42 Yoshida H, Kijima H, Terasaki Y, Takeshita T, Omiya H, Shimojima K, et al. Heterogenous expression of nm23 gene product as a predictor of lymph nodal status in human breast cancer. Int J Oncol 1998;13:1141–6.[ISI][Medline]

43 Terasaki-Fukuzawa Y, Kijima H, Suto A, Takeshita T, Iezumi K, Sato S, et al. Decreased nm23 expression, but not Ki-67 labeling index, is significantly correlated with lymph node metastasis of breast invasive ductal carcinoma. Int J Mol Med 2002;9:25–9.[ISI][Medline]

44 Tokunaga Y, Urano T, Furakawa K, Kondo H, Kanematsu T, Shiku H. Reduced expression of Nm23-H1, but not of Nm23-H2, is concordant with the frequency of lymph-node metastasis of human breast cancer. Int J Cancer 1993;55:66–71.[ISI][Medline]

45 Niu Y, Fu X, Lv A, Fan Y, Wang Y. Potential markers predicting distant metastasis in axillary node-negative breast carcinoma. Int J Cancer 2002;98:754–60.[CrossRef][ISI][Medline]

46 Leone A, Seeger RC, Hong CM, Hu YY, Arboleda MJ, Brodeur GM, et al. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene 1993;8:855–65.[ISI][Medline]

47 Hailat N, Keim DR, Melhem RF, Zhu X-X, Eckerstrom C, Brodeur GM, et al. High levels of p19/nm23 protein in neuroblastoma are associated with advanced disease and N-myc gene amplification. J Clin Invest 1991;88:341–5.[ISI][Medline]

48 Chang C, Zhu X-x, Thoraval D, Ungar D, Rawwas J, Hora N, et al. Nm23-H1 mutation in neuroblastoma. Nature 1994;370:335–6.[CrossRef][ISI][Medline]

49 Engel M, Seifert M, Theisinger B, Seyfert U, Welter C. Glyceraldehyde-3-phosphate dehydrogenase and Nm23-H1/Nucleoside diphosphate kinase A. Two old enzymes combine for the novel Nm23 protein phosphotransferase function. J Biol Chem 1998;273:20058–65.[Abstract/Free Full Text]

50 Paravicini G, Steinmayr M, André E, Becker-André M. The metastasis suppressor candidate nucleoside diphosphate kinase Nm23 specifically interacts with members of the ROR/RZR nuclear orphan receptor subfamily. Biochem Biophys Res Comm 1996;227:82–7.[CrossRef][ISI][Medline]

51 Baillat G, Gaillard S, Castets F, Monneron A. Interactions of Phocein with Nucleoside diphosphate kinase, Eps15, and Dynamin I. J Biol Chem 2002;277:18961–6.[Abstract/Free Full Text]

52 Roymans D, Vissenberg K, DeJonghe C, Engler RW, Kimura N, Grobben B, et al. Identification of the tumor metastasis suppressor Nm23-H1/Nm23-R1 as a constitutent of the centrosome. Exp Cell Res 2001;262:145–53.[CrossRef][ISI][Medline]

53 Lombardi D, Sacchi A, D’Agostino G, Tibursi G. The association of the Nm23-M1 protein and beta-tubulin correlates with cell differentiation. Exp. Cell Res 1995;217:267–71.[CrossRef][ISI][Medline]

54 Du J, Hannon G. The centrosomal kinase Aurora-A/STK15 interacts with putative tumor suppressor NM23-H1. Nucleic Acids Res 2002;30:5465–75.[Abstract/Free Full Text]

55 Otero A. Co-purification of vimentin, energy metabolism ensymes and a MER5 homolog with nucleoside diphosphate kinase. Identification of tissue-specific interactions. J Biol Chem 1997;272:14690–4.[Abstract/Free Full Text]

56 Nosaka K, Kawahara M, Masuda M, Satomi Y, Nishino H. Association of nucleoside diphosphate kinase nm23-H2 with human telomeres. Biochem Biophys Res Comm 1998;243:342–8.[CrossRef][ISI][Medline]

57 Fournier H, Dupe-Manet S, Bouvard D, Laconbe M, marie C, Block M, et al. Integrin cytoplasmic domain-associated protein 1a (ICAP-1a) interacts directly with the metastasis suppressor nm23-H2, and both proteins are targeted to newly formed cell adhesion sites upon integrin engagement. J Biol Chem 2002;277:20895–902.[Abstract/Free Full Text]

58 Subramanian C, Cotter M, Robertson E. Epstein-Barr virus nuclear protein EBNA-3C interacts with the human metastatic suppressor Nm23-H1: a molecular link to cancer metastasis. Nat Med 2001;7:350–5.[CrossRef][ISI][Medline]

59 Reymond A, Volorio S, Merla G, Al-Maghtheh M, Zuffardi O, Bulfone A, et al. Evidence for interaction between human PRUNE and nm23-H1 NDPKinase. Oncogene 1999;18:7244–52.[CrossRef][ISI][Medline]

60 Yaguchi H, Ohkura N, Tsukada T, Yamaguchi K. Menin, the multiple endocrine neoplasia type 1 gene product, exhibits GTP-hydrolyzing activity in the presend of the tumor metastasis suppressor nm23. J Biol Chem 2002;277:38197[Abstract/Free Full Text]

61 Fishbach M, Settleman J. Specific biochemical inactivation of oncogenic ras proteins by nucleoside diphosphate kinase. Cancer Res 2003;63:4089[Abstract/Free Full Text]

62 Palacios F, Schweitzer J, Boshans R, D’Souza-Schorey C. ARF6-GTP recruits Nm23-H1 to facilitate dynamin-mediated endocytosis during adherens junctions disassembly. Nat Cell Biol 2002;4:929[CrossRef][ISI][Medline]

63 Otsuki Y, Tanaka M, Yoshii S, Kawazoe N, Nakaya K, Sugimura H. Tumor metastasis suppressor nm23H1 regulates Rac GTPase by interaction with Tiam1. Proc Natl Acad Sci USA 2001;98:4385–90.[Abstract/Free Full Text]

64 Zhu J, Tseng Y-H, Kantor J, Rhodes C, Zetter B, Moyers J, et al. Interaction of the Ras-related protein associated with diabetes Rad and the putative tumor metastasis suppressor NM23 provides a novel mechanism of GTPase regulation. Proc Natl Acad Sci USA 1999;96:14911–8.[Abstract/Free Full Text]

65 Tseng Y, Vincent D, Zhu J, Adeyinka A, Moyers J, Watson P, et al. Regulation of growth and tumorigenicity of breast cancer cells by the low molecular weight GTPase Rad and Nm23. Cancer Res 2001;61:2071–9.[Abstract/Free Full Text]

66 Fan Z, Beresford P, Oh D, Zhang D, Lieberman J. Tumor suppressor NM23-H1 is a granzyme A-Activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell 2003;112:659–72.[ISI][Medline]

67 Postel E, Abramczyk B. Escherichia coli nucleoside diphosphate kinase is a uracil-processing DNA repair nuclease. Proc Natl. Acad Sci USA 2003;100:13247–52.[Abstract/Free Full Text]

68 Postel E. Multiple biochemical activities of NM23/NDP kinase in gene regulation. J Bioenerg Biomem 2003;35:31–40.[ISI][Medline]

69 Siddiqui-Jain A, Grand C, Bearss D, Hurley L. Direct evidence for a G-quadruplex in a promoter region and its targeting with a samll molecule to repress c-MTC transcription. Proc Natl Acad Sci USA 2002;99:11593–8.[Abstract/Free Full Text]

70 Cuello F, Schulze R, Heemeyer F, Meyer H, Lutz S, Jakobs K, et al. Activation of heterotrimeric G proteins by a high energy phosphoate transfer via nucleoside diphosphate kinase (NDPK) B and Gb subunits. J Biol Chem 2003;278:7220–6.[Abstract/Free Full Text]

71 Wagner P, Vu N-D. Phosphorylation of ATP-citrate lyase by nucleoside diphosphate kinase. J Biol Chem 1995;270:21758–64.[Abstract/Free Full Text]

72 Wagner P, Vu N-D. Histidine to aspartate phosphotransferase activity of nm23 protein: phosphorylation of Aldolase C on Asp 319. Biochem J 2000;346:623–30.[CrossRef][ISI][Medline]

73 Freije JMP, Blay P, MacDonald NJ, Manrow RE, Steeg PS. Site-directed mutation of Nm23-H1. Mutations lacking motility suppressive capacity upon transfection are deficient in histidine-dependent protein phosphotransferase pathways in vitro. J Biol Chem 1997;272:5525–32.[Abstract/Free Full Text]

74 Wagner PD, Steeg PS, Vu N-D. Two-component kinase like activity of Nm23 correlates with its motility suppressing activity. Proc Natl Acad Sci USA 1997;94:9000–5.[Abstract/Free Full Text]

75 Wang F, Cao Y, Zhao W, Liu H, Fu Z, Han R. Taxol inhibits melanoma metastases through apoptosis induction, angiogenesis inhibition and restoration of E-cadherin and nm23 expression. J Pharmacol Sci 2003;93:197–203.[CrossRef][ISI]

76 Ouatas T, Halverson D, Steeg P. Dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor expression in metastatic human breast carcinoma cells: new uses for old compounds. Clin Cancer Res 2003;9:3763–72.[Abstract/Free Full Text]

77 Liu F, Qi H-L, Chen H-L. Effects of all-trans retinoic acid and epidermal growth factor on the expression of nm23-H1 in human hepatocarcinoma cells. J Cancer Res Clin Oncol. 2000;126:85–90.[ISI][Medline]



             
Copyright © 2004 Oxford University Press (unless otherwise stated)
Oxford University Press Privacy Policy and Legal Statement